Seattle Genetics plans second trial of its drug SGN-15

Herald news services

BOTHELL — Seattle Genetics Inc. on Thursday announced it will start a second-phase clinical trial with one of its lead drug candidates, SGN-15.

The trial will evaluate the monoclonal antibody-drug conjugate SGN-15 in combination with the chemotherapeutic drug Taxotere for patients with hormone refractory prostate cancer. The study is planned for as many as 15 sites in the United States, with the lead site at Arizona Cancer Center in Tucson.

United flights canceled: United Airlines canceled more than 100 flights Thursday for the second straight day in an escalation of operational turmoil it blames on its mechanics, who have been working without a contract. The airline attributed 85 of its 105 cancellations by midafternoon to maintenance problems — a percentage that spokesman Joe Hopkins said is "elevated significantly from where we think it should be."

AT&ampT Wireless gains partner: AT&ampT Corp. is selling 16 percent of its Redmond-based wireless business for $9.8 billion to NTT DoCoMo, Japan’s top mobile phone company, giving AT&ampT new funds and a savvy partner in the drive to deliver mobile Internet services. Also on Thursday, the wireless group turned to Nordic rivals Ericsson and Nokia for the latest in mobile phone technology as AT&ampT revealed plans to upgrade its wireless network with the GSM cell phone technology used throughout Europe and Asia.

Retail sales modest: The outlook for the holiday shopping season grew more uncertain Thursday after the nation’s largest retailers reported modest November sales gains that were achieved only by heavy discounting over the Thanksgiving weekend. While some stores did well, especially value-oriented chains like Wal-Mart Stores Inc., many retailers fell victim to slowing consumer spending.

Talk to us

You can tell us about news and ask us about our journalism by emailing newstips@heraldnet.com or by calling 425-339-3428.
If you have an opinion you wish to share for publication, send a letter to the editor to letters@heraldnet.com or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
More contact information is here.